

Patients with metastatic urinary tract cancer treated with pembrolizumab (n = 241)

Without prior platinum-based chemotherapy (n = 4)
Without available treatment response data (n = 13)
Non-urothelial cancer (n = 1)
With missing baseline data (n = 1)
Without progression following chemotherapy (n = 58)

Patients for the analysis (n = 164)

the KEYNOTE-045 criteria

Trial-eligible patients (n = 89)

Trial-ineligible patients (n = 75)